Advanced wound care is a fast growing market mainly composed of 4 main categories: dressings, wound cleansers, negative pressure wound therapy devices and biologics.
The global market value was $9,4 bn in 2015 and it is expected to reach $13,1 bn in 2022, with a compound annual growth rate (CAGR) of 4,7 %1.
Among the leading categories of advanced wound care, wound cleansers are expected to attain $2,1bn in 2023, growing at a CAGR of 5,4%1 from 2016 to 2023. The main drivers of this growth are the aging population and the increased prevalence of chronic diseases, such as diabetes.
It is estimated that 1 % to 2 % of the population will experience a chronic wound during their lifetime in developed countries2 and this rate is increasing year after year. Stalled wounds may persist for months, even years3,4 before healing.
Due to this situation, non-healing wounds represent an economic burden for health services and patients. In 2015 only, chronic wounds represented a global expenditure of $143 bn.
Stalled wounds also have a psychological and social impact on patients: infection, delays in wound healing and wound associated pain strongly affect patients' life.
For these reasons, reducing healing time and pain for patients has become a priority.
Historically, wound cleansers were used solely to remove contaminants, foreign debris and exudate or for irrigation. In recent years, Wound Bed Preparation (WBP) is the emerging evidence-based approach that has been developed to promote healing of non-healing wounds.
The WBP approach is internationally recognized by the major wound care associations.
According to this, wound cleansers may actually play a crucial role to support healing by removing local barriers to healing while minimizing harm to wound tissue.
The principal local barriers to healing are bioburden & biofilm5,6 and high levels of proinflammatory mediators7-8.
Until today, no available wound cleanser matched the ideal profile in terms of safety and efficacy: an evolution is needed.
Thanks to its optimal efficacy and safety, Nexodyn AOS, the Tehclo based solution, is the first wound cleanser proven to restart healing.